Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia is feasible in clinical practice based on recently published international recommendations. Nevertheless, factors predictive of molecular recurrence have not been fully elucidated and long-term follow-up of pati...

Full description

Bibliographic Details
Main Authors: Stéphanie Dulucq, Franck E. Nicolini, Delphine Rea, Pascale Cony-Makhoul, Aude Charbonnier, Martine Escoffre-Barbe, Valérie Coiteux, Pascal Lenain, Françoise Rigal-Huguet, Jixing Liu, Agnès Guerci-Bresler, Laurence Legros, Jean-Christophe Ianotto, Martine Gardembas, Pascal Turlure, Viviane Dubruille, Philippe Rousselot, Juliana Martiniuc, Henry Jardel, Hyacinthe Johnson-Ansah, Bertrand Joly, Tawfiq Henni, Emilie Cayssials, Patricia Zunic, Marc G. Berger, Bruno Villemagne, Fanny Robbesyn, Stephane Morisset, François-Xavier Mahon, Gabriel Etienne
Format: Article
Language:English
Published: Ferrata Storti Foundation 2022-05-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/10662

Internet

https://haematologica.org/article/view/10662

Similar Items